Skip to main content
OpenTrials
Completed

NCT Number: NCT01978132

Primary Hyperaldosteronism and Ischemia-reperfusion Injury

Patients with primary hyperaldosteronism experience more cardiovascular events compared to patients with primary hypertension, independent of the blood pressure level.

In this research we hypothesize that patients with primary hyperaldosteronism are more susceptible to ischemia-reperfusion injury.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radboud University Medical Centre

Nijmegen, Gelderland, 6525EZ, Netherlands

About this study

Patients with PHA have an increased risk of cardiovascular events, independent of blood pressure level. Also in patients suffering a myocardial infarction, circulating aldosterone levels are associated with increased mortality. In animal models of myocardial infarction, the administration of exogenous aldosterone increased infarct size, although other studies did not report this effect. In similar models, antagonists of the mineralocorticoid receptor (MR) reduced infarct size, which was completely abolished in ecto-5'-nucleotidase (CD73, the enzyme that catalyses extracellular formation of the endogenous nucleoside adenosine) and adenosine receptor knock-out mice. Therefore, we hypothesize that patients with PHA have an increased susceptibility for ischemia-reperfusion (IR)-injury due to down-regulation of the enzyme CD73. We will use the reduction in brachial flow-mediated dilation (FMD) by forearm IR as a well-validated endpoint for (endothelial) IR-injury.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with primary hyperaldosteronism:

  • Age 18-75 years
  • Confirmed primary hyperaldosteronism (aldosterone >0.28 nmol/l after salt loading)
  • Serum potassium ≥ 3.5 mmol/L (with or without potassium supplementation)
  • Written informed consent

Inclusion criteria

patients with primary hypertension:

  • Age 18-75 years
  • Primary hypertension
  • Baseline aldosterone <0.30 nmol/l and aldosterone-renin-ratio<0.09
  • Serum potassium ≥ 3.5 mmol/L
  • Written informed consent

Exclusion criteria

for both arms (patients with primary hyperaldosteronism and patients with primary hypertension:

  • Smoking
  • History of atherosclerotic disease (myocardial infarction (MI), stroke, or peripheral vascular disease)
  • Not possible to change the antihypertensive medication into only diltiazem with or without hydralazine, according to the treating physician.
  • Not possible to temporarily interrupt statin treatment, if the patient use statins, according to the treating physician.
  • Severe renal dysfunction (MDRD < 30 ml/min)
  • Second/third degree AV-block on electrocardiography
  • Cardiac failure
  • Diabetes Mellitus
  • Use of acetylsalicylic acid and NSAID's theophylline, and dipyridamole

Treatment and study plan

forearm ischemia and reperfusion

Procedure

both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.

Primary outcomes

  1. brachial FMD

    Time frame: 1 day morning

    primary outcome measure is the reduction in brachial artery FMD after 20 minutes of forearm ischemia and 20 minutes of reperfusion in patients with primary hyperaldosteronism (compared to patients with primary hypertension)

Secondary outcomes

  1. CD73 and adenosine

    Time frame: one day morning (just before FMD experiment)

    Blood will be drawn to determine circulating adenosine concentration and the CD73 activity on mononuclear cells

Other outcomes

  1. aldosterone and renin

    Time frame: 1 day

    Just before the FMD experiment, blood will be drawn for aldosterone and renin levels. These levels will not be determined, unless the brachial artery FMD after ischemia and reperfusion is significantly reduced in patients with primary hyperaldosteronism. We will store the plasma and serum at -20 C. If applicable, the aldosterone and aldosterone-to-renin ratio will be determined to correlate the primary outcome measure to the aldosterone and ARR levels.

  2. leukocyte telomere length (LTL)

    Time frame: 1 day

    We will measure LTL in 12 patients with PHA and 12 patients with EHT to assess wether aldosterone excess increases telomere shortening in patients with PHA

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Registry information

Official study title

Primary Hyperaldosteronism and Endothelial Ischemia-reperfusion Injury

Acronym: PHA-FMD

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Nov 7, 2013
Registry last updated
Oct 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.